Clinical Trial Update: An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

View source ↗

Summary

This clinical trial update reports on an observational study of Rituxan/MabThera (rituximab) plus chemotherapy as first-line treatment for diffuse large B-cell …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma

Drugs mentioned

• Rituxan/MabThera (rituximab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Diffuse Large B-Cell Lymphoma | Status: COMPLETED